Background Two billion peripheral intravenous catheters (PIVCs) are used globally each year, but optimal dressing and securement methods are not well established. We aimed to compare the efficacy and costs of three alternative approaches to standard non-bordered polyurethane dressings.
Introduction
Peripheral intravenous catheters (PIVCs) are the most common invasive medical devices used in hospitals. Around two billion devices are sold globally each year, and most patients who are admitted to hospital require intravenous therapy. [1] [2] [3] PIVC failure is unacceptably com mon: up to 69% of devices require removal due to dislodgement, phlebitis, occlusion, infiltration, or infec tion. [4] [5] [6] [7] PIVC failure can lead to pain and anxiety, interrupted therapy, and morbidity and mortality associated with infection, and additional procedures are often needed to replace catheters, all of which substan tially increases healthcare costs and workloads.
Effective dressing and securement should prevent many PIVC complications, such as dislodgement from the vein and micromotion of the device within the vessel, which precipitate venous inflammation, occlusion, and entry of skin site bacteria into the PIVC wound. 8, 9 Global clinical practice guidelines 10, 11 state that PIVC dressings should be clean, dry, and intact, and that devices should be well secured. However, 21-71% of PIVC dressings are soiled, moist, loose, or inadequately secured at any timepoint. 1, 12 Traditional PIVC dressings are commerciallymanu factured, sterile, adhesive, transparent poly urethane films, with sterile gauze used as an alternative for diaphoresis. 10, 13 Nonsterile tape is commonly used in addition to the dressing with both approaches. Increasing evidence 10 suggests that polyurethane dressings provide inadequate securement. Additional reinforced tape or cloth border (ie, bordered poly urethane), adhesive securement devices applied in addition to the dressing, and cyanoacrylate adhesive added to the PIVC entry point under the dressing might improve securement. These additions increase purchase cost and complexity, but would be desirable if PIVC failure was prevented.
Few studies have investigated the effect of dressings and methods of securement for PIVCs on patient safety. A 2015 Cochrane review 14 reported that available evidence is of low quality and no superior method has been identified. In this study, we compared the efficacy and costeffectiveness of, and patient and clinician satisfaction with, traditional lowcost polyurethane and three alter natives (bordered polyurethane, securement devices with polyurethane, and tissue adhesive with polyurethane), with the aim of assisting policy makers with decision making about the best choice of dressing and securement for PIVCs.
Methods

Study design and participants
We did a pragmatic, randomised controlled, parallel group superiority trial at two hospitals in Queensland, Australia (Princess Alexandra Hospital and Royal Brisbane and Women's Hospital). Research nurses screened medical and surgical departments for partici pants. Patients were eligible if they were 18 years or older and required a PIVC for clinical treatment, which was expected to be required for longer than 24 h. We excluded nonEnglish speaking patients without interpreters, and patients who had PIVCs inserted through damaged skin, severe diaphoresis, or known allergy to any study product. Palliative patients, patients deemed to be at high risk of a skin tear by clinicians, and patients who had previously been included in the study were also excluded. Written, informed consent was obtained from all patients or their representatives. The study was approved by the research ethics committees of Princess Alexandra Hospital, Royal Brisbane and Women's Hospital, and Griffith University. The protocol has been published previously. 15 
Randomisation and masking
Patients were randomly assigned (1:1:1:1) to tissue adhesive with polyurethane, bordered polyurethane, securement device with polyurethane, or polyurethane using a
Research in context
Evidence before this study We searched MEDLINE, CINAHL, Cochrane Collaboration databases, the Australian New Zealand Clinical Trials registry, and ClinicalTrial.gov from database inception until Sept 5, 2017 , for randomised controlled trials comparing any dressing types and securement methods for peripheral intravenous catheters (PIVCs). We used the search terms "peripheral", "intravenous", "catheter/device/cannula", "dressing", "securement", "polyurethane/transparent/occlusive", "gauze", "tape", "failure", "phlebitis", "infection", "occlusion", "dislodgement/accidental removal/migration", "infiltration", "premature removal" and "complications", with no language or date restrictions. We also searched the reference lists of identified articles. This search retrieved nine relevant studies. A previous trial of 360 patients found that tissue adhesive with bordered polyurethane significantly reduced PIVC failure compared with polyurethane. We published a systematic review in 2015 (last search April 8, 2015) , of six trials including a total of 1539 participants. Of four product comparisons, only one contained data from more than one randomised controlled trial, and the overall quality of evidence was low. Our systematic review reported that non-bordered polyurethane dressings were associated with less dislodgement than gauze with tape, but the effect on phlebitis and infiltration was unclear. Individual trials assessed in our previous systematic review reported that bordered polyurethane reduced dislodgement, but increased the incidence of phlebitis compared with securement devices. No previous studies have conclusively identified the optimum dressing and securement method for PIVCs. Some studies were limited to particular patient groups, outcome measures often assessed one type of complication rather than overall PIVC failure, and costs were rarely considered.
Added value of this study
In this study, no significant differences in PIVC failure were identified between the four intervention groups. We found that total costs (ie, dressing and securement products, staff time, response to PIVC failure and treatment of infections) were not significantly different between the four approaches. However, if treatment costs associated with infection were removed from cost analysis, polyurethane was the least expensive option. PIVC failure was common in all four intervention groups, and all products had poor durability, often requiring reinforcement. Skin adverse events occurred in a small number of patients in all groups.
Implications of all the available evidence
Our trial showed that none of the PIVC dressing or securement interventions tested were superior to low-cost polyurethane with regard to PIVC failure, suggesting that choice of PIVC dressing or securement should be selected mainly on the basis of cost. Our study highlights an unmet need for the innovation of dressing and securement methods to prevent PIVC failure.
centralised webbased randomisation service with random block sizes, stratified by hospital. Allocation was concealed until after patient consent was obtained, at which time the research nurses contacted the randomisation service, and advised the PIVC inserter of the allocation and documented this. Due to the nature of the intervention, patients, clinical and research staff were not masked to allocation, however, infection endpoints were adjudicated by a blinded rater. A study manager trained and supervised research nurses, and audited data quality and randomisation compliance.
Procedures
The study products (figure 1) were chosen as the global market leaders in their category, and were available in Australia. Royal Brisbane and Women's Hospital was defined as site 1, and Princess Alexandra Hospital was defined as site 2.
Patients assigned to the polyurethane group served as the control group. Unbordered polyurethane Tegaderm 1624W or 1626W transparent film dressings (3M, St Paul, MN, USA) were used to affix the PIVC in this group. Product size was determined by the hospital staff inserting the PIVC to suit individual patients and the insertion site (approximately 60% of polyurethane dressings were 6 cm × 7 cm [1624W] and 40% were 10 × 12 cm [1626W]).
Patients assigned to the tissue adhesive with poly urethane group, had 1-2 drops of cyanoacrylate (Histoacryl Blue, BBraun, Ann Arbor, MI, USA) applied to the PIVC insertion wound and 1-2 drops under the PIVC hub (and PIVC wings if present). The PIVC was held in position for around 10 s before the polyurethane was applied.
Patients assigned to the bordered polyurethane group had 10 × 7 cm Tegaderm I.V Advanced Secure ment dressings (3M) placed on the PIVC. The secure ment dressing had a central polyurethane component with a reinforced adhesive border on three sides.
Patients assigned to the securement device with polyurethane group had polyurethane and either a StatLock IV Select Stablization Device (Bard Access Systems, Salt Lake City, UT, USA; site 1), or a GripLok Medium Universal Securement Device (TIDI, Neenah, Wisconsin, USA; site 2) applied to the PIVC. The securement devices were selected to suit the winged or nonwinged PIVC used routinely at each site. Securement devices were placed outside of the polyurethane.
One strip of Micropore nonsterile tape (approximately 12•5 cm; 25 mm × 9•1 mm; 3M) was applied on the short extension set in all four groups, with the exception of the securement device with polyurethane group at site 2 because the product used for this group was able to secure the extension set.
PIVCs were inserted by ward nurses and doctors or expert nurse inserters without the use of ultrasound according to standard operating procedures. PIVC site, catheter gauge, and attachments were chosen by the inserter depending on the needs of each individual patient. Preinsertion skin disinfection was done using SoluPrep Swabs (2% chlorhexidine in 70% isopropyl alcohol; 3M) at site 1, and Persist Plus Skin Prep Swabs (1% chlorhexidine in 70% isopropyl alcohol; BD Medical, Sandy, UT, USA) at site 2. PIVCs were nonwinged Insyte Autoguard BC with Blood Control Technology (BD Medical) at site 1, and winged Introcan Safety 3 (B Braun, Sheffield, UK) at site 2. SmartSite needlefree valves (BD Medical; site 1 and 2) or MaxPlus clear needlefree connectors (BD Medical; site 2) were connected to PIVCs directly or via an extension set. At site 1, 10 cm extension sets were used with bonded 3way Connecta (BD Medical) or a 15 cm luer lock extension for patients in the securement device group. 15 cm extension sets were used at site 2 (BD Medical).
One PIVC was assessed per patient (the first for each patient that met the inclusion criteria). All postinsertion care was provided by clinical staff. Bedside nurses decided if replacement or reinforcement of study products was required (eg, when products became loose, moist, or soiled) during PIVC dwell. Research nurses recorded product replacements or modifications and advised staff about study products before the study and during the trial. The decision to remove PIVCs was made by clinical staff. The PIVC removal policy at site 1 was initially only on completion of therapy or because of complications, which changed during our trial to a 72-96 h removal policy. Site 2 had a routine 72-96 h removal policy throughout the study with stricter enforcement. At both sites, dwell time could be extended to more than 96 h if the PIVC was still required, no signs or symptoms of catheter dysfunction or infection were observed, and the decision was clinically justified (eg, the patient had difficult anatomy).
Research nurses visited patients daily while the PIVC was in place, or until adverse events involving the skin had resolved. Baseline patient and PIVC characteristics were recorded. During PIVC dwell, data were collected on PIVC therapy, dressing and securement type and condition, and insertion site condition (redness, pain, tenderness, swelling, purulence, palpable cord or vein streak). At PIVC removal, research nurses recorded complications, dwell time, clinical variables (eg, antibiotic treatment, infusion tubing securement), and overall patient satisfaction with the study products using an 11point ordinal scale (0=completely dissatisfied, 10=completely satisfied) if possible. Research nurses also asked the nurse who removed the products to verbally rate the difficulty of removal using an 11point ordinal scale (0=very difficult, 10=very easy). 48 h after PIVC removal, research nurses checked the hospital pathology system for blood, PIVC tip, or insertion site culture results.
All data were entered into a secure, portable electronic device using the REDCap database and formbased interface. Clinical staff did not have access to this data and continued routine practices for PIVC monitoring. A project manager audited data quality, completeness, and protocol adherence, visiting sites at least once a month for training and monitoring.
As per routine clinical practice, medical staff ordered blood, PIVC tip, or site swab cultures if patients were suspected to have PIVCassociated infections. These samples were obtained by bedside nurses, processed in the hospital pathology laboratory by blinded staff, and results were accessed by researchers. Infection outcomes were blindrated by an infectious diseases physician.
To further determine infection risk associated with the study products, a substudy of PIVC tip and insertion site skin cultures was done by a blinded microbiologist. 12, 16 Convenience sampling was used (ie, samples were taken when research nurses were available at the time of PIVC removal), and samples were then cultured within 24 h.
Outcomes
The primary outcome was allcause PIVC failure (ie, unplanned PIVC removal before completion of therapy) as a composite of the following complications at removal: complete dislodgement (entire PIVC dislodged from patient's body), occlusion (PIVC would not infuse or leakage when fluid was infused), phlebitis (defined by the presence of one or more of the following symptoms: pain or tenderness, redness, swelling, purulence with or without a palpable cord), or infection (primary bloodstream infection or laboratory confirmed local PIVC infection). 13, 17 Secondary outcomes were subtypes of PIVC failure (complete dislodgement, occlusion, phlebitis, and infection), PIVC and study product dwell time (defined as time from insertion to removal), cost per patient (direct cost to the hospital for device management and cost of PIVC replacements), PIVC colonisation (>15 colony forming units) and skin colonisation (>0 colony forming units) assessed in a substudy of a convenience sample of 10% of patients (ie, devices that were removed when research nurses were available to take cultures), 16 and overall patient satisfaction with the product and staff satisfaction with removal of the product, which were verbally ranked using a 11point ordinal scale.
Research nurses assessed patients daily for adverse events potentially associated with the study products including rash, blister, itchiness, in addition to adhesive residue or skin tears on product removal. Serious adverse events (ie, death, admission to intensive care, or primary bloodstream infections) were monitored using hospital records and reported to the human research ethics committee at each site.
Total resource use and costs were calculated for each group. Costanalysis included products applied at PIVC insertion and staff time taken to apply these, cost of replacement products, reinforcement, and additional PIVC insertions, and the cost of treatment for local or bloodstream infections. Details of the cost analysis are shown in the appendix. 
Statistical analysis
On the basis of a previous trial 5 at these study sites, which reported that prevalence of PIVC failure using poly urethane was 40%, we hypothesised that each of the three alternatives would reduce PIVC failure by 10% (ie, to 30%), which was considered to be clinically significant. 20, 21 Sample sizes were calculated for three superiority tests of two proportions: a sample size of 388 patients per group conferred 90% power, with onesided p=0·05, to detect an absolute difference of 10% in PIVC failure rates between the three intervention groups and the control group, with expected attrition rates of 10%. We did not use α level adjustment, consistent with our study design of separate hypothesis testing of the effect of multiple alternative treatments (ie, the hypo thesis test did not inform a single claim of effectiveness) on one primary endpoint, with a shared control group. 22 Data cleaning involved checks of missing, outlier and improbable values with source data verification and corrections for around 10% of patients. Categorical data were summarised as counts and proportions, and con tinuous data as mean (SD) or median (IQR), if not normally distributed. Comparability of groups at baseline for risk of device failure was assessed using clinical criteria (ie, the probablility that differences would influence the primary outcome). Missing data for primary and secondary endpoint variables were not imputed.
The primary analysis was by modified intention to treat (ITT), which included all randomly assigned patients for whom data on the primary endpoint were available. We calculated the relative incidence of PIVC failure and compared this between each intervention group and the control group using Fisher's exact test. We calculated PIVC failure per 100 days with incidence rate ratios and 95% CIs to summarise the effectiveness of each intervention. We used KaplanMeier survival curves with log rank MantelCox tests to compare failure over time. Multivariate Cox regression was used to calculate hazard ratios (HRs) for PIVC failure, adjusted for treatment group, for variables associated with PIVC failure at p<0•2 on bivariate regression, and for study site because of significant differences in mean PIVC dwell times (ie, different duration of exposure to risk). We did prespecified sensitivity analyses to assess the variance in effect sizes between study sites.
Secondary endpoints were compared between groups using parametric (Cox regression) or nonparametric (Wilcoxon rank sum) tests.
The primary outcome was also analysed in the per protocol population, which included all patients who received one of the four study interventions for a duration of at least 24 h from PIVC insertion, with censoring if the treatment was modified (ie, if additional products were added after insertion). A cost analysis was done from the perspective of public hospitals, because they are the main purchasers of PIVC dressings and securements. Mean costs (including costs of responding to all adverse events) for the three treatment groups were compared, using the polyurethane group as the control, using nonparametric bootstrapping. p<0•05 was considered to indicate statistical signifi cance. All statistical analyses were done with Stata (version 15.1). The trial was not overseen by a Data Safety Monitoring Committee because patient accrual was rapid. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12611000769987.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author has full access to all the data in the study and had final responsibility to submit for publication.
Results
Between March 18, 2013, and Sept 9, 2014, we screened 2382 patients and randomly assigned 1807 patients to receive tissue adhesive with polyurethane (n=446), bordered polyurethane (n=454), securement device with polyurethane (n=453), or polyurethane (n=454; figure 2). Patient accrual ended when the planned sample size was reached. Of 1807 randomly assigned patients, 98 (5%) had a failed or cancelled PIVC insertion and thus were excluded from the primary analysis (figure 2). No patients withdrew consent. Primary endpoint data was not available for 12 patients, thus 1697 (99%) of 1709 patients who had a PIVC inserted were included in the modified intentiontotreat analysis. 115 408 PIVC dwell h (4809 PIVC days) were studied. Of the 1697 patients who had a PIVC inserted, 281 (17%) had the PIVC removed on day 1 (ie, the first day of insertion), 445 (26%) on day 2, 337 (20%) on day 3, 276 (16%) on day 4, 157 (9%) on day 5, 88 (5%) on day 6, 55 (3%) on day 7, 27 (2%) on day 8, 11 (1%) on day 9, 12 (1%) on day 10, and 20 (1%) between days 11 and 18. Clinical and demographic characteristics were similar between groups for both patients and PIVCs ( (table 2) . The differences in absolute risk between the three intervention groups and the control group were less than the 10% hypothesised difference, indicating that none of the three interventions were superior to the control intervention. No significant differences in PIVC failure were identified between the three intervention groups and the control group (p=0•21 to 0•74, table 2), or PIVC failure per 100 PIVC days (p=0•25 to 0•82, table 2). Time to failure was similar between the three inter vention groups and the control groups (p=0•57; figure 3 ). Prespecified sensitivity analyses revealed that the incidence of absolute PIVC failure incidence differed by site, however, PIVC failure per 100 h was not statistically different between the two sites (all p>0•05), and there was no confounding of intervention group HRs by site.
1685 (99%) of 1709 patients who had a PIVC inserted received the allocated intervention (figure 2). Of the remaining 24 patients, 17 received a different study inter vention to that they were assigned to and seven received nonstudy products. 1122 (67%) of 1679 patients required additional dressings or securements (303 [71%] of 427 patients in the tissue adhesive with polyurethane group; 257 [61%] of 423 patients in the bordered polyurethane group; 238 [56%] of 425 patients in the securement device with polyurethane group; 324 [77%] of 422 patients in the polyurethane group). 1100 patients had one of the four interventions for a duration of more than 24 h and thus were included in the per protocol analysis set. Perprotocol analysis of the primary outcome showed that a significantly lower proportion of patients in the tissue adhesive with polyurethane group had PIVC failure than the polyurethane control group, however, no significant differences in PIVC failure were identified between the control group and the bordered Data are n, n (%), or median (IQR). PIVC=peripheral intravenous catheter. *Classified according to the Fitzpatrick scale. 23 †Skin was disinfected with a 70% alcohol swab in five patients. Skin disinfection data was not available for 18 patients. ‡Extension tubing was required to apply securement devices. §1363 patients had infusion tubing for one day or more. Device and skin colonisation were not significantly different between any of the intervention groups and the control group (table 3) .
The initial mean costs were substantially higher per patient for products and staff time for all three experimental groups compared with the control group (table 4). When the costs of replacement for failed PIVC devices and replacement or reinforcement of study products were included in the costanalysis, costs were signifi cantly higher per patient for all three experimental groups compared with the control group (all p<0·001). However, overall mean costs per patient were not significantly different between any experimental group and the control group when treatment costs for the three primary bloodstream infections were included.
17 (4%) of 427 patients in the tissue adhesive with polyurethane group, two (<1%) of 423 patients in the bordered polyurethane group, eight (2%) of 425 patients in the securement device with polyurethane group, and seven (1%) of 422 patients in the polyurethane group had skin adverse events. 39 skin adverse events were associ ated with study products (rash Patients and bedside nurse satisfaction scores were generally high for all products tested (table 3) . Median patient satisfaction scores were significantly higher in the tissue adhesive with polyurethane group than the polyurethane group, whereas nurse satisfaction scores were signifi cantly lower (table 2) , however these differences were equivalent to less than one point on the 11point scale.
Discussion
Overall, 41% of patients had allcause PIVC failure. We compared three alternative dressings and securements with lowcost polyurethane dressing, but none of the interventions significantly reduced PIVC failure. Costs were not significantly different between groups. However, excluding costs for infection treatment from the cost analysis showed that the total mean cost per patient of polyurethane was significantly less than any of the three alternatives, representing savings of up to AU$15·53 (95% CI 15·27-15·78) per patient. All products tested, including polyurethane, were associated with PIVC failure, and often needed reinforcement. Thus, innovation to develop effective, durable products is urgently needed.
This study indicates that substantial savings could be made for the Australian health system if clinicians use low cost polyurethane dressings for PIVCs, in the absence of clinical rationale for use of a more expensive product. 24, 25 A crosssectional study 1 of 40 620 PIVCs in 51 countries reported that 22 747 (56%) devices were secured with polyurethane, 8936 (22%) with bordered polyurethane, and 2031 (5%) with securement devices, however, data on use of tissue adhesive were not available, but its use has been reported in other studies.
26,27
Two billion PIVCs are used globally each year, thus using polyurethane for all PIVC insertions instead of other securement devices and dressings could save $3·4-13·7 billion per year in products, staff time, and responses to PIVC failure (excluding infections). however, no differences were identified between the two interventions with regard to complication and PIVC failure rates, consistent with the results of smaller studies. 27, 28 Furthermore, the durability of polyurethane and bordered polyurethane (one of which was used in all four study groups) was poor and reinforcement was frequently required, often due to loss of adherence of the dressing. Reinforcement was needed in 67% of patients, indicating the poor durability of these interventions, even with a short PIVC dwell time (median 2·3 days). A small randomised trial, 27 reported that fewer patients who had securement devices with polyurethane had PIVC failure than did patients with polyurethane dressings, however, this difference was not statistically significant, and no such benefit was seen in our study.
The proportion of patients who had occlusions was significantly lower in the tissue adhesive with poly urethane group than the polyurethane group, although the 6% absolute reduction was less than the 10% reduction in PIVC failure observed in a smaller study (52 [27%] of 190 patients vs 31 [17%] of 179 patients), which followed patients for a shorter PIVC dwell time (maximum 48 h). 26 Tissue adhesive is applied directly at the PIVC skin entry point and under the PIVC hub, possibly reducing micromotion and internal vein damage. 27 Our perprotocol analysis further suggested that tissue adhesive had potential benefit, but many patients required additional dressing reinforcement, and its use in combination with polyurethane alone is unlikely to benefit the hospital population at large. When durable dressings are identified, tissue adhesive might be a useful adjunct in the future. The incidence of bloodstream infections was low, which precludes definitive conclusions about comparative infection risk between study products. However, no patients in the tissue adhesive group had infections, which suggests that tissue adhesive has antimicrobial properties, 29 or in the securement device group, which could indicate that securement devices prevent PIVC micromotion, restricting the entry of skin microorganisms into the wound.
A large, prospective cohort study 30 supports the need for extra securement to reduce PIVC failure and the limitations of current approaches. Any additional secure ment (eg, tape, elasticised tube, or additional dressing) added to bordered polyurethane was associated with significant reductions in occlusion, phlebitis, and dis Initial dressing and securement products
Staff time costs to apply products* $0·81 $0·72 $1·21 $0·60 $0·84
Costs associated with initial PIVC
Replacement PIVC †, dressing and securement products, and staff time
Costs associated with initial and replacement PIVC $17·78 (2·67)
Difference in mean costs compared with polyurethane control
Difference in total cost compared with polyurethane control
Data are mean AU$, or mean AU$ (SD). PIVC=peripheral intravenous catheter. *SDs not available because costs were calculated on the basis of weighted mean times. †Replacement PIVCs were required by 97 patients in the tissue adhesive with polyurethane group, 118 patients in the bordered polyurethane group, 113 patients in the securement device with polyurethane group, and 110 patients in the polyurethane control group. ‡Non-parametric bootstrapping. §Two patients in the bordered polyurethane group and one patient in the polyurethane control group had primary bloodstream infections. ¶SDs not available because only two patients in the bordered polyurethane group and one patient in the polyurethane group had primary bloodstream infections. Table 4 : Mean cost per patient associated with PIVC dressings and securements by treatment group in the modified intention-to-treat population lodgement. 30 These associations suggest multiproduct combinations (ie, securement bundles) might be more effective for prevention of PIVC failure than any one product alone, and should be assessed in randomised studies.
To our knowledge, no previous study has systematically assessed skin adverse events associated with PIVCs. In this study, skin adverse events were reported in 2% of patients. Rashes were most common, possibly reflecting irritation from the adhesive, or incorrect application of the dressing to skin when it was still moist from preinsertion antiseptics. Bruising was observed at the PIVC insertion site in 68 (4%) of 1697 patients at baseline, which is likely to reflect traumatic insertion since ultrasound and other vein identification technologies were not used.
Strengths of this study were the rigorous randomisation, daily followup, and prospective data collection processes. We chose a pragmatic design, to understand how the inter ventions worked under realworld conditions, inc luding the intrahospital and interhospital hetero geneity typical of PIVC care. Allcause PIVC failure was the primary endpoint and is often used in PIVC trials since the common outcome is a nonfunctional device. Generalisability of results was maximised by the hetero geneity of patients and PIVCs studied, with many of the included participants at high risk of PIVC failure due to age, obesity, and multiple comorbidities. Postinsertion care of PIVCs was provided by bedside staff to increase the applicability of our results to the real world. Although 5% of patients who were randomly assigned did not have a PIVC inserted and were therefore excluded, this was not affected by the choice of dressing and securement product.
The microcosting approach used for our costanalysis, which included detailed costing for staff time associated with study products, is also a strength. Although the protocol specified a costeffectiveness analysis to estimate incremental cost per PIVC failure, 15 we considered this of little value since no group had superior primary outcomes. Instead, our economic analysis is pragmatic and incorporates costs of the interventions and those of managing complications and adverse events. In keeping with the hospital perspective, costs incurred after patient discharge were not studied, which is a potential limitation. However, the cost of treatment for primary bloodstream infection-the complication most likely to incur costs after patient discharge-were assessed until hospital discharge, by which time all primary bloodstream infections had resolved, thus our approach was unlikely to have altered study conclusions.
Most PIVC insertions were done by expert nurse inserters, which might have reduced the risk of PIVC failure, and thus this could be considered a limitation. However, the incidence of PIVC failure is consistent with our previous studies, 5, 30 which used less experienced inserters, thus poor securement might outweigh the benefits of optimal insertion. Intensive care units were not included because PIVCs are rarely used in Australian intensive care units. Intervention group allocation was not concealed in the study due to the nature of the products and interventions used, and we did not formally assess interrater reliability, but we limited the risk of bias by using a small number of trained observers and clear definitions and masked infection outcome asses sors (100% agree ment), and the study was super vised and audited by a study manager. We have previously established 98% agreement (Cohen's kappa co efficient 0·33) for phlebitis measures. 8 Although our proto col specified a two criteria definition of phlebitis, we used a one criteria definition since clinicians commonly recorded only the main reason for PIVC removal (eg, pain). This should not have introduced bias, since the outcome of PIVC failure. Different PIVC and securement devices were used at the two study sites, but no significant confounding in effect sizes was found by site, suggesting that this did not introduce bias. We tested various product categories (eg, bordered polyurethane), but results might not reflect all product types within these categories, or be generalisable to other patient groups, such as children. Our sample size was adequate to test our apriori hypotheses of 10% absolute reduction in the primary endpoint for all three inter vention groups, but observed reductions ranged between 2 and 5%. A sample size of approximately 3000 patients would be required to confirm the largest observed difference in PIVC failure (38% in tissue adhesive with polyurethane group vs 43% in the polyurethane group) with 80% power at p=0•05. We acknowledge that views 22, 31, 32 differ, but we did not use alpha adjustment because our study design tested separate hypotheses of three alternative treatments, rather than varying doses of the same treatment, for one primary endpoint against a shared control group.
The Centers for Disease Control Guidelines 13 and the Infusion Therapy Standards of Practice 10 consider optimal PIVC dressing and securement unresolved. Both documents reflect the conclusions of a 2015 systematic review and metaanalysis, 14 which highlighted the paucity of high quality randomised studies. At present, regulatory bodies do not require evidence of efficacy for device registration in contrast to pharmaceuticals, and manu facturers and independent funders rarely support randomised trials to investigate efficacy or cost effectiveness. The extensive global use of PIVCs, high prevalence of PIVC failure, and substantial costs to healthcare providers for dressing and securement products highlights the need for further investment and innovation to develop effective products.
Most patients who are admitted to hospital for treatment worldwide require PIVC insertion, of whom up to half require device removal because of complications, which lead to substantial waste, dis comfort, cost, and harm. Improved dressings and secure ment of PIVCs is likely to prevent many complications, but the optimal method remains elusive. Until a superior method is identified, cost should be the main consideration with regard to product choice.
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